DEFA14A: NovaBay Pharmaceuticals Completes Eyecare Business Sale, Adjourns Special Meeting on Dissolution Proposal

NovaBay Pharmaceuticals has finalized the sale of its Avenova eyecare business for $11.5 million and further adjourned its special meeting to allow more time for stockholders to vote on the company's dissolution.

Summary

• NovaBay Pharmaceuticals has completed the sale of its Avenova eyecare business to PRN for $11.5 million.
• The sale was approved by stockholders at a special meeting reconvened on January 16, 2025.
• The special meeting has been further adjourned to January 30, 2025, to allow more time for stockholders to vote on the proposal to dissolve the company.
• Approximately 49% of outstanding shares voted in favor of the dissolution proposal at the January 16th meeting, but it requires 50% to pass.
• The company believes that dissolving the company after the asset sale is the best way to maximize value for stockholders.
• 86.7% of the shares that voted on the dissolution proposal as of January 16, 2025, voted in favor.
• Stockholders are encouraged to vote on the dissolution proposal by January 29, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company selling its main asset and seeking dissolution, despite the positive language used by management. The repeated delays in the special meeting also indicate underlying issues.

Positives

• The sale of the eyecare business for $11.5 million allows the company to monetize a valuable asset.
• The company believes the dissolution provides the best opportunity to optimize value for stockholders.
• A significant majority (86.7%) of the shares that voted on the dissolution proposal as of January 16, 2025, voted in favor.

Negatives

• The dissolution proposal has not yet reached the required 50% threshold of outstanding shares for approval.
• The special meeting has been adjourned multiple times to secure enough votes for the dissolution.

Risks

• There is a risk that the dissolution proposal will not be approved if the required 50% threshold is not met.
• The company is in the process of winding down operations, which may present challenges.
• The company's future is dependent on the successful completion of the dissolution process.

Future Outlook

The company intends to pursue the dissolution and wind-up of the company if the dissolution proposal is approved by stockholders.

Management Comments

• The divestiture of our eyecare business has allowed us to monetize this valuable asset and to return value to our stockholders, while providing the Avenova brand an opportunity to grow, flourish and reach its full potential in the future, said Justin Hall, NovaBay CEO.
• This transaction brings significant change to NovaBay, ending one chapter and creating an exciting new opportunity for the Avenova brand.
• We will be excited to see the brand thrive in the years to come.
• We appreciate the support of our stockholders in approving this transaction.

Industry Context

The sale of the eyecare business suggests a strategic shift for NovaBay, moving away from its previous focus and towards a potential wind-down of operations. This is not a common move in the pharmaceutical industry, where companies typically seek to expand their product portfolios.

Comparison to Industry Standards

• The sale of a business unit for $11.5 million is a relatively small transaction in the pharmaceutical industry, where deals often involve hundreds of millions or billions of dollars.
• Companies like Alcon or Bausch + Lomb, which are major players in the eyecare market, have significantly larger revenues and market capitalizations than NovaBay.
• The decision to dissolve the company is unusual, as most pharmaceutical companies seek to grow and develop new products rather than liquidate their assets.

Stakeholder Impact

• Shareholders will receive value from the asset sale and potential liquidation, but the company will cease to exist.
• Employees will likely be impacted by the dissolution of the company.
• Customers of the Avenova brand will now be served by PRN.

Next Steps

• Stockholders are encouraged to vote on the dissolution proposal by January 29, 2025.
• The special meeting will reconvene on January 30, 2025, to finalize the vote on the dissolution proposal.
• If the dissolution proposal is approved, the company will proceed with liquidation and wind-up.

Key Dates

Keywords

NovaBay Pharmaceuticals, Avenova, eyecare business, asset sale, dissolution, liquidation, stockholders, PRN, special meeting, proxy vote